Valence8 US LP Invests $466,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Valence8 US LP bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) during the third quarter, HoldingsChannel reports. The institutional investor bought 8,025 shares of the company’s stock, valued at approximately $466,000. Keros Therapeutics makes up approximately 0.2% of Valence8 US LP’s portfolio, making the stock its 21st largest position.

A number of other large investors have also recently bought and sold shares of KROS. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics during the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the second quarter worth about $128,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $53.84 on Friday. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -10.33 and a beta of 1.23. Keros Therapeutics, Inc. has a one year low of $27.31 and a one year high of $73.00. The company’s 50 day moving average price is $59.33 and its 200 day moving average price is $52.29.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the company posted ($1.33) earnings per share. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. Sell-side analysts forecast that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KROS. Guggenheim began coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Cantor Fitzgerald started coverage on Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Wedbush restated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.